Traditionally, high-throughput screening (HTS) has been employed excessively during early drug discovery to identify compounds binding to a single target of interest. Nowadays, we experience the shift in research and development toward modulating agents and, more prominently, on small molecules acting simultaneously on a variety of receptors to remedy an indication or disease of interest. In order to increase the outcome of HTS, novel approaches had to be and in fact have been developed. Accomplishing these goals may be attended by more detailed considerations of biological pathways and deeper integration with computational resources.
28 May, 2013
Monoclonal antibodies (mAbs) are remarkably versatile protein molecules with numerous applications in human health. More than 30 mAb therapeutics have been approved for marketing and approximately 360 mAbs are currently in clinical studies, with 30 in pivotal trials. The indications of these studies are diverse and include autoimmune disorders, solid and hematological cancers, and infectious diseases. In the preclinical arena, understanding mAb interactions with their targets is also vital to vaccine design. This Drug Discovery Today Editor’s Choice newsletter provides timely reviews on the utility of antibodies as therapeutics and approaches to mAb/antigen interaction studies that aid in vaccine development.
14 May, 2013
The latest issue of Drug Discovery Today is packed full of industry focused research articles, new developments in drug discovery, and expert comment and opinion.
13 May, 2013